Extendicare Inc
TSX:EXE
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Extendicare Inc
TSX:EXE
|
CA |
|
Viasat Inc
F:VS1
|
US |
|
B
|
Bavarian Nordic A/S
SWB:BV3
|
DK |
|
nCino Inc
F:6NCA
|
US |
|
Daiei Kankyo Co Ltd
OTC:DKCLF
|
JP |
|
F
|
Fluor Corp
XBER:FLU
|
US |
|
M
|
Microsoft Corp
SGO:MSFT
|
US |
|
D
|
Deutsche Balaton AG
XBER:BBHK
|
DE |
|
E
|
Envista Holdings Corp
NYSE:NVST
|
US |
|
Sartorius AG
F:SRT3
|
DE |
|
Stitch Fix Inc
NASDAQ:SFIX
|
US |
|
G
|
GlaxoSmithKline PLC
XBER:GS7
|
UK |
|
Cigniti Technologies Ltd
NSE:CIGNITITEC
|
IN |
|
Pieris Pharmaceuticals Inc
NASDAQ:PIRS
|
US |
|
Medx Health Corp
XTSX:MDX
|
CA |
|
N
|
Neogenomics Inc
F:NG9
|
US |
Wall St Price Targets
EXE Price Targets Summary
Extendicare Inc
According to Wall Street analysts, the average 1-year price target for EXE is 37.15 CAD with a low forecast of 22.98 CAD and a high forecast of 45.15 CAD.
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.
What is EXE's stock price target?
Price Target
37.15
CAD
According to Wall Street analysts, the average 1-year price target for EXE is 37.15 CAD with a low forecast of 22.98 CAD and a high forecast of 45.15 CAD.
What is the Revenue forecast for Extendicare Inc?
Projected CAGR
14%
Over the last 14 years, the compound annual growth rate for Revenue has been -2%. The projected CAGR for the next 3 years is 14%.
What is the Operating Income forecast for Extendicare Inc?
Projected CAGR
20%
Over the last 14 years, the compound annual growth rate for Operating Income has been 1%. The projected CAGR for the next 3 years is 20%.
What is the Net Income forecast for Extendicare Inc?
Projected CAGR
19%
The compound annual growth rate for Net Income over the next 3 years is 19%.
